Evolus Reports Q3 Revenue Growth and Positive Adjusted EBITDA
Evolus reported 13% year-over-year revenue growth and its fourth consecutive quarter of positive adjusted EBITDA. The company reaffirmed its full-year 2026 financial outlook.
Story updates
09:07:40 PM UTC
SquawkNews
Evolus reported Q3 2026 revenue growth of 13% year over year and a fourth consecutive quarter of positive Adjusted EBITDA. Global toxin revenue grew approximately 11% and HA gel portfolio revenue grew nearly 40% year over year; full-year 2026 outlook was reaffirmed.Material DetailsContext by AI Ana…
09:09:52 PM UTC
SquawkNews
Global Net Revenue of $78.0 Million for the Third Quarter of 2026, an Increase of 13% Over the Prior
Evolus, Inc. (NASDAQ:EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced its financial results for the third quarter ended September 30, 2026.“Our third quarter results demonstrate the continued strength of our commercial ex…